Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles

References

• Chen R, Zheng RS, Zhang SW, et al. Analysis of incidence and mortality of esophageal cancer in China, 2015. Zhonghua Yu Fang Yi Xue Za Zhi. 2019;53(11):1094–1097. doi:10.3760/cma.j.issn.0253-9624.2019.11.004.31683393
   PubMedGoogle Scholar
• Wei J, Wu ND, Liu BR. Regional but fatal: intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22(33):7478–7485. doi:10.3748/wjg.v22.i33.7478.27672270
   PubMed Web of Science ®Google Scholar
• Macrì A, Morabito F. The use of intraperitoneal chemotherapy for gastric malignancies. Expert Rev Anticancer Ther. 2019;19(10):879–888. doi:10.1080/14737140.2019.1671189.31544548
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20(Suppl 1):111–121. doi:10.1007/s10120-016-0662-9.27803990
   PubMed Web of Science ®Google Scholar
• Kurtz F, Struller F, Horvath P, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. Gastroenterol Res Pract. 2018;2018:2743985. doi:10.1155/2018/2743985.30473706
   PubMed Web of Science ®Google Scholar
• Shinkai M, Imano M, Chiba Y, et al. Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase ii trial. Anticancer Res. 2018;38(10):5975–5981. doi:10.21873/anticanres.12945.30275228
   PubMed Web of Science ®Google Scholar
• Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a Phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–1581. doi:10.1245/s10434-011-1631-5.21431408
   PubMed Web of Science ®Google Scholar
• Harstrick A, Bokemeyer C, Scharnofkse M, et al. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol. 1993;33(1):43–47. doi:10.1007/BF00686021.8269588
   PubMed Web of Science ®Google Scholar
• Li Y, Liu B, Yang F, et al. Lobaplatin induces BGC-823 human gastric carcinoma cell apoptosis via ROS-mitochondrial apoptotic pathway and impairs cell migration and invasion. Biomed Pharmacother. 2016;83:1239–1246. doi:10.1016/j.biopha.2016.08.053.27565846
   PubMed Web of Science ®Google Scholar
• Yin CY, Lin XL, Tian L, et al. Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis. World J Gastroenterol. 2014;20(46):17426–17433. doi:10.3748/wjg.v20.i46.17426.25516654
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep. 2018;20(8):62. doi:10.1007/s11912-018-0703-0.29884974
   PubMed Web of Science ®Google Scholar
• Coccolini F, Fugazzola P, Ansaloni L, et al. Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy. Acta Biomed. 2018;89(8–S):104–109. doi:10.23750/abm.v89i8-S.7904.
   PubMedGoogle Scholar
• Stehlin JS Jr, Greeff PJ, Giovanella BC, et al. Dramatic response of cancer to localized hyperthermia. N Y State J Med. 1980;80(1):70–72.6928525
   PubMedGoogle Scholar
• Hornung M, Werner JM, Schlitt HJ. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Expert Rev Anticancer Ther. 2017;17(9):841–850. doi:10.1080/14737140.2017.1357470.28715968
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240. doi:10.1056/NEJMoa1708618.29342393
   PubMed Web of Science ®Google Scholar
• Russell MC, Staley CA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. J Oncol Pract. 2016;12(10):938–939. doi:10.1200/JOP.2016.016584.27858557
   PubMed Web of Science ®Google Scholar
• Murata S, Yamamoto H, Naitoh H, et al. Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer. J Surg Oncol. 2017;116(8):1159–1165. doi:10.1002/jso.24771.28743181
   PubMed Web of Science ®Google Scholar
• Ye J, Ren Y, Wei Z, et al. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: a retrospective cohort study. Surg Oncol. 2018;27(3):456–461. doi:10.1016/j.suronc.2018.05.025.30217302
   PubMed Web of Science ®Google Scholar
• Hua S, Kong X, Chen B, et al. Anticancer mechanism of lobaplatin as monotherapy and in combination with paclitaxel in human gastric cancer. Curr Mol Pharmacol. 2018;11(4):316–325. doi:10.2174/1874467211666180813095050.30101722
   PubMed Web of Science ®Google Scholar
• Huang XE, Wei GL, Huo JG, et al. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev. 2013;14(4):2611–2614. doi:10.7314/apjcp.2013.14.4.2611.23725184
   PubMedGoogle Scholar
• Peng Z, Xu S, Li H, et al. Advanced gastric cancer with brain metastasis effectively treated by arterial infusion chemotherapy: a case report. Oncol Lett. 2014;7(2):449–451. doi:10.3892/ol.2013.1699.24396466
   PubMed Web of Science ®Google Scholar
• Zhou HT, Jiang J, Guan X, et al. The short-term effect analysis of intraoperative intraperitoneal perfusion chemotherapy with lobaplatin for colorectal cancer. J BUON. 2019;24(2):442–448.31127989
   PubMed Web of Science ®Google Scholar